Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | AAN highlights: NMOSD and MOGAD

Friedemann Paul, MD, Charité-Universitätsmedizin Berlin, Berlin, Germany, shares his highlights from the American Academy of Neurology (AAN) Annual Meeting. Follow-up data from open-label extensions for all three newly approved NMOSD treatments are available and were discussed at the meeting. The new MOGAD diagnostic criteria were also an important topic at the meeting. The recently published diagnostic criteria allow better discrimination between MOGAD and multiple sclerosis as well as serum-negative NMOSD. This interview took place at the AAN Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Grants or contracts: German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Roche, Parexel and Almirall.
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene.
Participation on a Data Safety Monitoring Board or Advisory Board: Celgene, Roche, UCB, Merck.
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Academic Editor PLos One, Associate Editor von Neurology® Neuroimmunology & Neuroinflammation.